Drug intelligence / Profile preview

anti-ACBP monoclonal antibody

Development stage: Preclinical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Parenteral

Overview

The anti-ACBP monoclonal antibody is a research-stage biologic designed to neutralize extracellular Acyl-CoA Binding Protein (ACBP), also known as Diazepam Binding Inhibitor (DBI). ACBP is a phylogenetically conserved protein that, when secreted, acts as a hunger signal and a negative regulator of autophagy. In preclinical studies, this neutralizing antibody has demonstrated hepatoprotective effects in murine models of liver ischemia/reperfusion injury, acetaminophen toxicity, and nonalcoholic steatohepatitis (NASH) by inducing autophagy and reducing inflammation and fibrosis. In the context of B-cell lymphoma, ACBP is implicated in glucocorticoid resistance and immune evasion; the antibody aims to restore dendritic cell antigen presentation and enhance antitumor immunity by blocking the ACBP-GABA_A receptor-TSC22D3 axis.

Other names: anti-diazepam binding inhibitor monoclonal antibodyanti-DBI monoclonal antibody

Targets

ACBP (Acyl-CoA-binding protein)

Beyond the preview

Go deeper on anti-ACBP monoclonal antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-ACBP monoclonal antibody.

Explore the full profile